Company profile: Onxeo
1.1 - Company Overview
Company description
- Provider of oncology drug R&D and platforms, offering Beleodaq (belinostat), a histone deacetylase inhibitor marketed in the US for injection; Livatag, a nanoparticle doxorubicin in Phase III for primary liver cancer; and pipeline programs including platON, a decoy oligonucleotide platform for cancer and inflammatory diseases; AsiDNA, a DNA-repair decoy; and VIO-01, a pan‑DDR decoy activating STING.
Products and services
- Belinostat / Beleodaq®: A histone deacetylase inhibitor injection marketed in the United States, assessed for hematological cancers and solid tumors, specifically treating peripheral T‑cell lymphoma
- AsiDNA™: A short double‑stranded DNA decoy fragment that mimics double‑strand breaks, inhibits tumor DNA repair pathways, and induces cancer cell death within malignant cells
- PlatON™: A proprietary decoy oligonucleotide chemistry platform that targets intracellular DNA‑binding proteins to generate candidate compounds for oncology and inflammatory disease indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Onxeo
Arc Medical
HQ: United Kingdom
Website
- Description: Provider of award-winning, innovative medical products designed to increase Adenoma Detection Rates (ADR) and improve retrieval methods, focusing on enhancing physician experience and patient outcomes with cost effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arc Medical company profile →
Iambic Therapeutics
HQ: United States
Website
- Description: Provider of an AI-driven drug-discovery platform to optimize drug profiles and identify novel mechanisms of action, featuring NeuralPlexer (3D physics-based generative diffusion for protein-ligand structures), OrbNet (protein-ligand binding energetics), PropANE (multi-parameter lead selection), and Magnet (generative molecular design), plus a first-in-class CDK2/4 candidate for cyclin D- and E-driven cancers with reduced off-target toxicities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iambic Therapeutics company profile →
Imunon
HQ: United States
Website
- Description: Provider of nucleic acid-based immunotherapy and vaccine platforms that harness the body's immune system, including TheraPlas, a nonviral delivery system for anti-cancer nucleic acid therapies initially targeting advanced ovarian cancer; PlaCCine, a multivalent nucleic acid vaccine platform for infectious diseases and cancer; FixPlas, for universal cancer vaccines; and IndiPlas, for personalized neoepitope cancer vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imunon company profile →
Cinfa Biotech
HQ: Spain
Website
- Description: Provider of biosimilars development and manufacturing exclusively in Europe, adhering to strict guidelines and highest European quality standards with specialist know-how. Founded in 2013 as part of the Spanish Cinfa Group; active in the global biosimilars market and currently has two products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cinfa Biotech company profile →
Odyssey Therapeutics
HQ: United States
Website
- Description: Provider of precision immunomodulators for inflammatory diseases and oncology medicines for cancer, enabled by a drug hunting engine combining machine learning, target biology, and medicinal chemistry. Offers target biology and discovery with CRISPR-based screening and advanced cell culture, proprietary small-molecule libraries, and predictive/data sciences.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Odyssey Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Onxeo
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Onxeo
2.2 - Growth funds investing in similar companies to Onxeo
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Onxeo
4.2 - Public trading comparable groups for Onxeo
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →